Difference between revisions of "Team:ASIJ Tokyo/Safety"

(Prototype team page)
 
 
(51 intermediate revisions by 6 users not shown)
Line 1: Line 1:
−
{{ASIJ_Tokyo}}
+
{{:Team:ASIJ_Tokyo/bar}}
 +
{{ASIJ_Tokyo/CSS}}
 
<html>
 
<html>
  
 +
<style type="text/css">
  
−
<div class="column full_size">
+
body, html {
 +
    height: 100%;
 +
    margin: 0;
 +
    font-family: "Avenir"!important;
 +
    background-color: #C7E0F3;
 +
}
  
−
<h1> Safety </h1>
+
#background {
−
<p>Please visit the <a href="https://2018.igem.org/Safety">Safety Hub</a> to find this year's safety requirements & deadlines, and to learn about safe & responsible research in iGEM.</p>
+
    background-image: url(https://static.igem.org/mediawiki/2018/7/70/T--ASIJ_Tokyo--%2ASafety_toppic%2A.jpg);
 +
    height: 580px;
 +
    background-position: center;
 +
    background-repeat: none;
 +
    background-size: cover;
 +
    position: relative;
 +
}
  
−
<p>On this page of your wiki, you should write about how you are addressing any safety issues in your project. The wiki is a place where you can <strong>go beyond the questions on the safety forms</strong>, and write about whatever safety topics are most interesting in your project. (You do not need to copy your safety forms onto this wiki page.)</p>
+
#yajirushi {
 +
    position: absolute;
 +
    bottom: 105px;
 +
    z-index: 1;
 +
    width: 100px;
 +
    height: 30px;
 +
    left: 45%;
 +
}
  
−
</div>
+
#header {
 +
    padding-top: 28px;
 +
}
  
 +
#wrapper {
 +
    margin-left: 10%;
 +
    margin-right: 10%;
 +
}
  
−
<div class="column two_thirds_size">
+
#click {
−
<h3>Safe Project Design</h3>
+
    position: absolute;
 +
    bottom: 38px;
 +
    width: 100px;
 +
    height: 30px;
 +
    left: 45%;
 +
}
  
−
<p>Does your project include any safety features? Have you made certain decisions about the design to reduce risks? Write about them here! For example:</p>
+
#titlebodytext {
 +
    font-size: 25px;
 +
    letter-spacing: 1px;
 +
}
  
−
<ul>
+
#bodytext {
−
<li>Choosing a non-pathogenic chassis</li>
+
    font-size: 17px;
−
<li>Choosing parts that will not harm humans / animals / plants</li>
+
    line-height: 1.5;
−
<li>Substituting safer materials for dangerous materials in a proof-of-concept experiment</li>
+
}
−
<li>Including an "induced lethality" or "kill-switch" device</li>
+
−
</ul>
+
  
−
</div>
+
#references {
 +
    font-size: 15px;
 +
    line-height: 1.5;
 +
}
  
−
<div class="column third_size">
+
#divider {
−
<h3>Safe Lab Work</h3>
+
  width: 5%;
 +
  backgound-color: #E07E7E;
 +
  size: 1px;
 +
}
  
−
<p>What safety procedures do you use every day in the lab? Did you perform any unusual experiments, or face any unusual safety issues? Write about them here!</p>
+
a{
 +
    color: #4B7FAD;
 +
    text-decoration: underline;
 +
}
  
−
 
+
a:visited {
−
<h3>Safe Shipment</h3>
+
    color: #4B7FAD;
−
 
+
}
−
<p>Did you face any safety problems in sending your DNA parts to the Registry? How did you solve those problems?</p>
+
</style>
 +
<body>
 +
<div id="background">
 +
<div id="yajirushi">
 +
<a href="#click">
 +
<img src="https://static.igem.org/mediawiki/2018/6/6a/T--ASIJ_Tokyo--downarrow.png" height="180px">
 +
</a>
 +
            </div>
 +
            <div id="click"></div>
 +
</div>
 +
<div id="wrapper">
 +
<h1 id="header"> SAFETY </h1>
 +
<hr>
 +
<p>
 +
<div id = "bodytext">
 +
Our lab at ASIJ is classified as Biosafety Level 1. This year the only type of organism we used was NEB 5-Alpha Competent K-12 E. Coli. Since these are lab grade E.coli and all plates/tubes containing E. coli were autoclaved before disposal, this posed no risks to our colleagues or community.
 +
<p>
 +
Furthermore, we follow the standard University lab safety for Japan, JNIOSH, the implementation of which was overseen by our building safety officer, Mr. Bhupesh Upadhyay. More information about JNIOSH can be found <a href="http://www.jniosh.go.jp/en/rule/links.html"><b>here.</b></a>
 +
<p>
 +
In the lab, we have standard fire and earthquake safety measures. For biological safety, we have an Eye Wash Station, Autoclave, Incubator, and PCR workstation with working HEPA filters.  In addition, we use bleach, a glass-only waste container, non latex gloves, lab coats, and safety goggles that are routinely sanitized in a UV goggle sanitizer unit.
 +
<p>
 +
We also had experts overseeing our project to manage any of the risks associated with our lab work. Beth Crissy, our Principal investigator, insured safety procedures were followed in the lab setting.  She has a long history of working with E.Coli and managing molecular biology lab.
 +
<p>
 +
Regarding our specific project, this system would be used in the human body to treat a mutational disease if it were to fully develop into a real product that people could use. Some of the ethical risks involved with such a use would be the possibility of a wider use of CRISPR for less non-therapeutic applications.
 +
<p>
 
</div>
 
</div>
−
 
−
 
 
</html>
 
</html>
 +
{{ASIJ_Tokyo/footer}}

Latest revision as of 16:07, 17 October 2018

SAFETY

Our lab at ASIJ is classified as Biosafety Level 1. This year the only type of organism we used was NEB 5-Alpha Competent K-12 E. Coli. Since these are lab grade E.coli and all plates/tubes containing E. coli were autoclaved before disposal, this posed no risks to our colleagues or community.

Furthermore, we follow the standard University lab safety for Japan, JNIOSH, the implementation of which was overseen by our building safety officer, Mr. Bhupesh Upadhyay. More information about JNIOSH can be found here.

In the lab, we have standard fire and earthquake safety measures. For biological safety, we have an Eye Wash Station, Autoclave, Incubator, and PCR workstation with working HEPA filters. In addition, we use bleach, a glass-only waste container, non latex gloves, lab coats, and safety goggles that are routinely sanitized in a UV goggle sanitizer unit.

We also had experts overseeing our project to manage any of the risks associated with our lab work. Beth Crissy, our Principal investigator, insured safety procedures were followed in the lab setting. She has a long history of working with E.Coli and managing molecular biology lab.

Regarding our specific project, this system would be used in the human body to treat a mutational disease if it were to fully develop into a real product that people could use. Some of the ethical risks involved with such a use would be the possibility of a wider use of CRISPR for less non-therapeutic applications.